The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
VJVirtual | Detection of ctDNA in patients with MCL and CLL
Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, The Peter MacCallum Cancer Centre, Melbourne, Australia, discusses data he has recently presented on circulating tumor DNA (ctDNA), and the utility of this technique in patients with Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma treated with ibrutinib or venetoclax. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
